The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignant tissues displayed moderate to strong cytoplasmic immunoreactivity, often accompanied with nuclear staining.
Most malignant cells displayed moderate cytoplasmic immunoreactivity. Strong nuclear and cytoplasmic staining was observed in malignant lymphomas, most colorectal cancers along with several lung, urothelial and pancreatic cancers.
Malignant cells showed moderate to strong cytoplasmic positivity, often accompanied with weaker nuclear staining.
Validation
Two (or more) antibodies yielding similar or partly similar staining patterns which are partly consistent with or contradicted by limited gene/protein characterization data
The multi-targeting antibody yielding a staining pattern consistent with gene/protein characterization data for all of the genes
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
